Enliven Therapeutics Inc ELVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
-
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
-
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 52
Comparables
Valuation
|
Metric
|
ELVN
|
SWTX
|
OLMA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.73 | 4.31 | 3.07 |
Price/Sales | — | 25.81 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ELVN
SWTX
OLMA
Financial Strength
|
Metric
|
ELVN
|
SWTX
|
OLMA
|
|---|---|---|---|
Quick Ratio | 14.13 | 7.49 | 9.04 |
Current Ratio | 14.39 | 7.91 | 9.13 |
Interest Coverage | — | — | — |
Quick Ratio
ELVN
SWTX
OLMA
Profitability
|
Metric
|
ELVN
|
SWTX
|
OLMA
|
|---|---|---|---|
Return on Assets (Normalized) | −23.51% | −32.86% | −35.73% |
Return on Equity (Normalized) | −25.09% | −37.78% | −39.18% |
Return on Invested Capital (Normalized) | −29.04% | −42.13% | −43.92% |
Return on Assets
ELVN
SWTX
OLMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rsslrvft | Pzvt | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lscfxnwxs | Wslrn | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rjvbvyvn | Htqyx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fymwbtqy | Sqbdnv | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Ndmmvgbkm | Hyzlx | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Crhnyzpxz | Jxfp | $28.1 Bil | |||
| Moderna Inc
MRNA
| Gdtlryc | Rcl | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Nymvxrwh | Fbfs | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zrmfzhtl | Ktbgw | $13.4 Bil | |||
| Incyte Corp
INCY
| Tmqmxrs | Bhtfb | $12.7 Bil |
United States